logologo
QuantliQuantli

Caris Life Sciences Inc

CAI

NASDAQ

Biotechnology

$21.80

USD

-0.38 (-1.71%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $6.27B

Volume 3.9M

Price (USD)
Price (USD)

About Caris Life Sciences Inc

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas and currently employs 1,846 full-time employees. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

CEO

Mr. David Halbert

HQ

Irving, TEXAS, US

Founded

2025

Employees

1,846

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

5 metrics our research team weighs before forming a view on CAI.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Gross Margin (TTM)

69.7%

Operating Margin (TTM)

15.5%

Net Margin (TTM)

10.6%

ROE (TTM)

17.8%

Free Cash Flow (TTM)

$123.96M

Financial Snapshot

Full Financials

Revenue

$989.61M

YoY

Gross Margin

70%

TTM

YoY

Net Income

$105.14M

YoY

Operating Cash Flow

$168.56M

YoY

Key Statistics

Open

$22.26

Previous Close

$22.18

Day Range

$21.45 - $22.43

52 Week Range

$14.19 - $42.50

Volume

3.9M

Average Volume (10 Days)

6.0M

Dividend Yield

Valuation Measurement

Market Cap

$6.27B

P/E Ratio (TTM)

59.62

P/S Ratio (TTM)

6.33

Price / Book

10.59

Financial Highlights

Profit Margin

10.6%

Return on Assets

8.6%

Return on Equity

17.8%

Revenue (TTM)

$989.61M

Net Income (TTM)

$105.14M

Diluted EPS (TTM)

$0.38

Total Cash (MRQ)

$690.91M

Levered FCF (TTM)

$123.96M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Go deeper on CAI

Similar Stocks

TVTX

Travere Therapeutics Inc

$62.14

+1.2%

ACAD

ACADIA Pharmaceuticals Inc

$28.24

-0.5%

SRRK

Scholar Rock Holding Corp

$52.52

-1.0%

MIRM

Mirum Pharmaceuticals Inc

$100.64

+1.9%

ERAS

Erasca Inc

$18.38

+2.9%

DYN

Dyne Therapeutics, Inc

$25.70

-1.0%

PTCT

PTC Therapeutics Inc

$71.70

-0.4%

COGT

Cogent Biosciences Inc

$37.93

+1.7%

DNTH

Dianthus Therapeutics Inc

$115.96

+5.8%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 03

Est. EPS

Adjusted consensus estimate

$0.04

Analyst Consensus

Buy

Based on 1 analyst ratings

Avg Target: $32.00

(+46.8% upside)

High: $32.00 · Low: $32.00

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

View full analyst ratings